Orion

Orion Forward P/E

The Forward P/E Ratio of Orion (271560.KS) as of Oct 31, 2026 is 14.38. In the previous year, Forward P/E Ratio was 10.49 — a change of 37.07% (higher).

Forward P/E

14.38

YoY

37.07%

Last updated:

Forward P/E Ratio of Orion is 2025 14.38 . Forward P/E Ratio of Orion was 2024 10.49 . It decreases by 37.07% higher compared to the previous year.

The Orion Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
39.34 KRW
Jan 1, 2019
25.52 KRW
Jan 1, 2020
20.56 KRW
Jan 1, 2021
21.35 KRW
Jan 1, 2022
14.02 KRW
Jan 1, 2023
14.61 KRW
Jan 1, 2024
10.49 KRW
Jan 1, 2025
14.38 KRW
The Orion Forward P/E history
YEARForward P/EYoY
14.38+37.07%
10.49-28.20%
14.61+4.17%
14.02-34.32%
21.35+3.83%
20.56-19.44%
25.52-35.13%
39.34-45.95%
72.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orion stock

Forward P/E Ratio of Orion is 14.38 in 2025.

Forward P/E Ratio of Orion changed from 10.49 to 14.38, representing a 37.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Orion since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Orion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Orion

All Key Metrics — Orion